16/10/2014 08:42:21

EXINI to arrange Bone Scan Index (BSI) symposium at important annual European congress

Lund, Sweden, 2014-10-16 09:42 CEST (GLOBE NEWSWIRE) --

EXINI and FUJIFILM RI Pharma will arrange a Bone Scan Index (BSI) symposium on

October 20th at this year’s EANM-congress (European Association of Nuclear

Medicine) held in Gothenburg, October 18-22.

The symposium called ”Bone Scan Index (BSI) A Nuclear Medicine Biomarker in

Metastatic Prostate Cancer”, commence at 13.00 p.m. For more information >>


”The symposium provide a unique opportunity for invited physicians within

nuclear medicine, to learn more about the imaging biomarker BSI and its

clinical applications. Arranging it together with our partner FUJIFILM RI

Pharma adds extensive clinical experience and insights gained from the success

of our product EXINI boneBSI (Bonenavi) on the Japanese market ”, comments

Magnus Aurell, CEO, EXINI Diagnostics AB.

Throughout the congress, several academic studies based upon use of the

software EXINI boneBSI and its BSI-calculating capacity, will be presented:

OP365: Prognostic value of bone scan index for treatment response and survival

in patients with high-risk prostate cancer. M. Reza, A. Bjartell, M. Ohlsson,

R. Kaboteh, P. Wollmer, L. Edenbrandt, E. Trägård

P491: Analytical validation of automated bone scan index as a candidate imaging

biomarker for advanced prostate cancer. A. Anand, L. Edenbrandt, A. Bjartell,

D. Minarik

P502: Reproducibility of automated bone scan index in patients with advanced

prostate cancer. A. Anand, L. Båth, R. Kaboteh, A. Bjartell, L. Edenbrandt

P786: Routine usefulness analysis of computer assisted diagnosis (CAD) software

for bone scan index L. Ferrer, M. Colombie, D. Rusu, D. Goulon, B. Jamet, N.

Varmenot, F. Kraeber-Bodere, C. Rousseau

More on Bone Scan Index (BSI):

BSI is an imaging biomarker providing fast, accurate and quantifiable

information to be used for diagnosis and stratification and the monitoring of

treatment response. It also provides increased accuracy in prognoses involving

patients suffering from skeletal metastases originating from prostate- or

breast cancer.

What is more, BSI has demonstrated its importance in the process of developing

new drugs, thus proving itself just as important for clinical use as for the

pharmaceutical industry. EXINI boneBSI is the only software capable of

extracting BSI-values for both these purposes.



For more information, please contact:

Magnus Aurell, CEO

Phone: +46 46 286 54 25

E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision

support to hospitals worldwide. The system is based on advanced image analysis

by artificial intelligence and can make its own interpretation of medical

images and provide diagnostic suggestions. In this way the system is used as a

decision support for the diagnosing doctor. EXINI is working with products for

the diagnosis of some of the most frequent endemic diseases such as cancer,

coronary heart disease, dementia and Parkinson's disease. The company was

founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock

market NASDAQ OMX First North and has about 600 shareholders. Principal owner

is Bo Håkansson. Consensus acts as Certified Adviser.


EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70

Lund, Sweden

Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com,


Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
10 Dec
Der er simpelhen så meget støj i marked omkring Vestas. Prøv at vurdere disse få tal, og din beslutn..
Hvem tør efterhånden investere på børsen, med dette ufatteligt ødelæggende shorting og naked-short v..
08 Dec
Der er et stykke historie omkring Zealand Pharma som jeg ikke har set nogen analytikler eller andre ..
07 Dec
Hold nu. Nu er de støjende skribenter endelig sendt i karantæne og der er en helt anden ro i debatte..
10 Dec
  @djks Tak for dine altid velovervejede indlæg, som er af stor betydning for debatten, idet man som..
12 Dec
Prøver du at dække dig ind under Bavarian for at undgå at vi snakker om dine enorme tab i Matas og R..
10 Dec
En julehilsen fra alpehue, og  et "Olympic" tillykke til Novo, dens aktionærer og verdens diabetespa..
07 Dec
Lidt spændende læsning og et overblik over det kæmpe potentiale som ligger i Veloxis.    https://www..
09 Dec
Lad mig prøve vs. Vestas at tage "prispres" fra en anden side, for der er også prispres i USA !!   M..
07 Dec
Lyt til amerikanerne. De ved trods alt hvad de taler om. Alle er vel enige om at PTC fortsætter uæn..

Man Group PLC : Form 8.3 - [Ladbrokes Coral Group plc]

13/12/2017 15:01:16
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Man Group Plc (b) Owner or controller..

Alliance Trust PLC : Net Asset Value(s)

13/12/2017 13:04:49
ALLIANCE TRUST PLC                                    At the close of business on Tuesday 12 December 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 791.0p -       including income, 794.4p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding in..

Investec Bank plc : Form 8.5 (EPT/RI) - Ladbrokes Coral Group plc

Related news
13/12/2017 09:50:50
 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
Sanofi : Sanofi presents R&D strategy and innovative pipeline
Japan’s Komatsu Selects NVIDIA as Partner for Deploying AI to Create Safer, More Efficient Construction Sites
Visionary Integration Professionals Supports Successful Launch of the Bureau of Cannabis Control Online Licensing Application System
ENDO INTERNATIONAL LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Endo International, Plc. To Contact The Firm
Capital Southwest Corporation Prices an Increased Public Offering of $50,000,000 - 5.95% Notes due 2022

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
13 December 2017 22:21:15
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171124.1 - EUROWEB4 - 2017-12-13 23:21:15 - 2017-12-13 22:21:15 - 1000 - Website: OKAY